Cure My Disease

Don't miss your cure!

 Log in / Sign up

50,000 scans, one goal: mapping how genes and environment shape heart and lung disease

NCT ID NCT06894095

NEW Knowledge-focused Sponsor: Jinling Hospital, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 16, 2026 · Last updated Oct 16, 2026

Summary

Researchers are building a large database that combines heart and lung imaging, genetic and molecular profiles, living environment details, and health records from adults who had a coronary CT scan. The study follows participants for up to 30 years to track heart attacks, strokes, deaths, and other cardiovascular events. By connecting these layers of data, the team aims to understand how genes and environment interact to drive heart and lung disease and to find better ways to prevent it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry links genes, living conditions, and imaging to heart and lung disease, it could reveal new targets for prevention and earlier treatment.
What could go wrong
This is an observational registry, so it can show patterns and associations but cannot prove that any one factor causes disease. Findings may take many years and may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

May 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutively enrolled individuals scheduled for coronary CTA, including those with known or suspected coronary artery disease (CAD) or individuals undergoing screening

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years * Coronary CT angiography performed * Informed consent acquired Exclusion Criteria: * Unable to complete the follow-up * Serious chronic kidney disease (eGFR\< 30 ml/min/1.73 m2) * Serious liver disease or dysfunction (chronic active hepatitis and cirrhosis, or aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 3 times the upper limit of normal) * Not appropriate to be tested due to birth planning, allergies, acute thyroid storm, etc. * Suspected or known infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), and Treponema pallidum (syphilis), etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Living environments Multi-omics Pulmonary-cardiovascular imaging

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Longjiang Zhang

    RECRUITING

    Nanjing, Jiangsu, 210002, China

  • Longjiang Zhang

    RECRUITING

    Suqian, Jiangsu, 223800, China

  • Longjiang Zhang

    RECRUITING

    Zhenjiang, Jiangsu, 212001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.